title: Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.
abstract: Several attempts have been made to replace aspirin with compounds without gastric toxicity; a cyclooxygenase-2 (COX-2) inhibitor, celecoxib, and a nitric oxide-aspirin, NCX-4016, have been developed for this purpose. This paper compares effects of celecoxib, NCX-4016 and aspirin on production of prostacyclin (PGI2) and thromboxane A2 (TXA2) and activation of the inducible form of nitric oxide synthase (iNOS) in infarcted heart in situ. Aspirin was most effective in reducing myocardial PGI2 synthesis and formation of TXA2. Myocardial effects of celecoxib resemble those of NCX-4016, although the two compounds have different modes of action.
authors.affiliation: Huntington Medical Research Institutes, Department of Experimental Cardiology, Pasadena, Calif 91101, USA.
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: N R
authors.initials: NR
authors.lastname: Kakar
authors.forename: E R
authors.initials: ER
authors.lastname: Vina
authors.forename: P E
authors.initials: PE
authors.lastname: Johnson
authors.forename: R J
authors.initials: RJ
authors.lastname: Bing
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000818:Animals; D001241:Aspirin / Q000031:analogs & derivatives / Q000494:pharmacology; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D011464:Epoprostenol / Q000096:biosynthesis; D006321:Heart / Q000187:drug effects; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis; D020030:Nitric Oxide Donors / Q000097:blood / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D011817:Rabbits; D013449:Sulfonamides / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000096:biosynthesis
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D020030:Nitric Oxide Donors; D010975:Platelet Aggregation Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D009569:Nitric Oxide; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; C102148:nitroaspirin; D000068579:Celecoxib; D001241:Aspirin